Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics, a biopharmaceutical company focused on iNKT cell therapies for cancer and immune diseases, has announced the acceptance of three abstracts for the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. The presentations will cover AgenT-797, including its persistence, tissue distribution, and anti-tumor activity. Abstracts will be released on November 9, 2021, with data also available on the investor section of their website post-presentation on November 12, 2021.